AETC National Coordinating Resource Center

François-Xavier Bagnoud Center

School of Nursing, Rutgers, The State University of New Jersey
65 Bergen Street, 8th floor
Newark, NJ 07101
United States

Phone
(973) 972-5141
Fax
(973) 972-0397

The AETC National Coordinating Resource Center provides education, training, and capacity building resources for the AETC Program to support the mission to offer timely, high quality, state-of-the-science information to healthcare professionals working with existing and emerging populations affected by HIV.

Principal Investigator
Phone: (973) 972-5141
Fax: (973) 972-0397
Program Director
Phone: (973) 972-6268
Fax: (973) 972-4263
Program Manager
Phone: (973) 972-9225
Marketing Coordinator
Phone: (973) 972-5528

Resources: 37

Title Sort ascending Publish Date Review Date
Self-care, Resiliency, and Stress Management for Healthcare Providers
Ryan White HIV/AIDS Program (RWHAP) Clinical Conference
Risk, Presentation, Treatment, and Outcomes of COVID-19 in People with HIV
Results and Response to a 10-State COVID-19 Practice Impact Survey in the Mountain West Region
Resources for Accessibility
Reaching People with HIV in Rural United States
Rapid (Immediate) ART Initiation & Restart: Guide for Clinicians
Prescribing PrEP: A Guide for Healthcare Providers
Prescribing nPEP Infographic
Post COVID Syndrome: An Overview and Approach to Management
Passport to Cure
Non-Occupational Post-Exposure Prophylaxis (nPEP) Toolkit
New Pandemic, Old Inequities: Impacts of COVID-19 and HIV on Marginalized Populations
Myths about Providing HCV Treatment to People with HIV with Substance Use Disorder(s)
Integrating Mental Health and Substance Use Care into HIV Primary Care Toolkit
Integrating Behavioral Health into Primary HIV Care — Covering the Bases
HIV/HCV Co-infection: An AETC National Curriculum
HIV Epidemic Rapid Response Toolkit
HIV & SARS-CoV-2 Webinar Series
HHS Adult ART Guidelines: Treatment-Experienced Patients
HHS Adult ART Guidelines: Transgender People with HIV
HHS Adult ART Guidelines: Initial Therapy
HHS Adult ART Guidelines: HIV and ART in Older People
Hepatitis C: Getting Cured Is Easier than Ever
Hep C Free Postcard
Flyer: Hepatitis C Screening and Treatment in People with HIV
Federal Training Centers Collaborative (FTCC) Virtual Learning Session Materials
Federal COVID-19 Resources
Evaluating AETC NCRC Partnerships for Impact
Direct-acting Antiviral (DAA) Prior Authorization Letter Templates
COVID-19, HIV, and Housing Instability
COVID-19 Resources for HIV Providers
Conducting a Primary or Acute Care HIV Telemedicine Visit
Community Health Worker Training Resources
Brand and Generic Names of ARVs in the United States and Mexico
Barriers to Curing Hepatitis C Virus among Coinfected People with HIV Infographic
Assisting HIV Patients Returning to Mexico and Central America / Asistiendo a los Pacientes que Regresan a México y Centroamérica

Articles: 51

Title Sort ascending Publish date Review date
Use of Dolutegravir in Dialysis
Updates in Antiretroviral Treatment during Pregnancy: Dolutegravir in Late Pregnancy
Updated CDC PrEP Guidelines
Undetectable = Untransmittable: Effective HIV Treatment Prevents HIV Transmission
U=U in PARTNER2 Study of MSM
Tissue Levels of TAF: Too Low for PrEP?
Tips for Successful Linkage to Care
Tenofovir Alafenamide (TAF) and Darunavir/Cobicistat in Pregnant Women
TargetHIV: New Name, New Look
Switching from TDF/FTC to TAF/FTC
START-ing TEMPRANO: Early Initiation of Antiretroviral Therapy for HIV
Safety of Dolutegravir at Conception: Updated Data
Rifampin Drug-Drug Interactions with Newer Antiretrovirals (TAF, Bictegravir, Dolutegravir)
Rapid ART Start
PrEP: TDF/FTC vs TAF/FTC in MSM
PrEP: Bone Density Improves after Stopping TDF/FTC
Possible Safety Issue with Dolutegravir during Pregnancy: Reports of Neural Tube Defects
On the Way: The First Protease Inhibitor-Based Single-Tablet Regimen
New ARV Approval - Fostemsavir
Naltrexone Improves Virologic Suppression
Long-acting Injectable PrEP: Cabotegravir
Long-acting Injectable PrEP Approved: Cabotegravir
Long-Acting Injectable ART: Cabotegravir + Rilpivirine
Immediate ART Initiation Improves Time to Viral Suppression
Ibalizumab Approved for Persons with Multidrug Resistant HIV
HIV-related Journal Articles from AETC-Affiliated Researchers and Faculty, 2021
HIV-related Journal Articles by AETC-Affiliated Researchers and Faculty, 2019-2020
HIV Meds Updates: Long-acting Injectable Therapy: Lenacapavir
HIV Meds Updates - TANGO and SALSA Studies: Switch to DTG/3TC from 3-Drug ART
HIV Meds Updates - Long-acting Injectable Therapy: Cabotegravir + Rilpivirine
HIV Meds Update: Treatment as Prevention: Suppressive ART, Condomless Sex, and HIV Transmission Risk - also a Word on HPTN 052
HIV Meds Update: PrEP Uptake by Sex, Race, and Age
HIV Meds Update: ART in Acute HIV--Decreasing HIV DNA
HIV Meds Update - RAPID: Immediate ART Initiation
HIV Care Tools – A New Resource for Ending the HIV Epidemic
FDA Approves 2-Drug Combination of Dolutegravir + Lamivudine
Efavirenz, Dolutegravir, and Darunavir: Pharmacokinetics during Pregnancy
Doravirine--New NNRTI Approved by FDA
Doravirine in Initial Therapy: DRIVE-AHEAD Study
Dolutegravir in Early Pregnancy: Updates on Possible Risk of Neural Tube Defects
Dolutegravir + 3TC in Initial Therapy
Darunavir/Cobicistat/FTC/TAF Single-Pill Combination in Treatment-Experienced Patients: EMERALD Study
Darunavir/Cobicistat/FTC/TAF Coformulation Approved; More Data from EMERALD Switch Study
CROI 2017: Failure of Dolutegravir Monotherapy
CROI 2017: Doravirine Noninferior to Darunavir + Ritonavir in Initial Treatment
CROI 2017: Dolutegravir in 2-Drug Simplification Studies
CROI 2017: Bictegravir and Dolutegravir, Head-to-Head Comparison
Bictegravir/TAF/FTC in Women
Bictegravir in Initial Therapy
Bictegravir Approved for Initial ART, in Combination with TAF/FTC
AETC Representation at the 2020 National Ryan White Conference on HIV Care & Treatment
Day Title
10/16 to 10/19 2022 Ryan White HIV/AIDS Program (RWHAP) CLINICAL CONFERENCE (California)
Sunday, October 16, 2022 - 8:00am EDT to Wednesday, October 19, 2022 - 5:00pm EDT
Event type: Conferences & Events